Myriad Genetics outlines $860M-$880M revenue target for 2026 while advancing cancer care continuum strategy
Source: SeekingAlpha
2026-02-23 22:55:24 ET
More on Myriad Genetics
- Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
- Myriad Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.06, revenue of $209.8M beats by $2.24M
- Myriad Genetics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy
Myriad Genetics Inc.
NASDAQ: MYGN
MYGN Trading
-0.97% G/L:
$5.13 Last:
678,039 Volume:
$4.96 Open:
MYGN Latest News
March 06, 2026 06:39:00 pm
Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
March 02, 2026 04:05:00 pm
Myriad Commercially Launches Precise MRD with Select Community Oncologists
MYGN Stock Data
$480,516,737
90,976,593
0.49%
72
N/A
Medical Diagnostics & Screening
Healthcare
US
Salt Lake City
